The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report
Top Cited Papers
- 10 January 2009
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (2), 298-303
- https://doi.org/10.1200/jco.2008.16.6876
Abstract
The International Neuroblastoma Risk Group (INRG) classification system was developed to establish a consensus approach for pretreatment risk stratification. Because the International Neuroblastoma Staging System (INSS) is a postsurgical staging system, a new clinical staging system was required for the INRG pretreatment risk classification system. To stage patients before any treatment, the INRG Task Force, consisting of neuroblastoma experts from Australia/New Zealand, China, Europe, Japan, and North America, developed a new INRG staging system (INRGSS) based on clinical criteria and image-defined risk factors (IDRFs). To investigate the impact of IDRFs on outcome, survival analyses were performed on 661 European patients with INSS stages 1, 2, or 3 disease for whom IDRFs were known. In the INGRSS, locoregional tumors are staged L1 or L2 based on the absence or presence of one or more of 20 IDRFs, respectively. Metastatic tumors are defined as stage M, except for stage MS, in which metastases are confined to the skin, liver, and/or bone marrow in children younger than 18 months of age. Within the 661-patient cohort, IDRFs were present (ie, stage L2) in 21% of patients with stage 1, 45% of patients with stage 2, and 94% of patients with stage 3 disease. Patients with INRGSS stage L2 disease had significantly lower 5-year event-free survival than those with INRGSS stage L1 disease (78% ± 4% v 90% ± 3%; P = .0010). Use of the new staging (INRGSS) and risk classification (INRG) of neuroblastoma will greatly facilitate the comparison of risk-based clinical trials conducted in different regions of the world.Keywords
This publication has 20 references indexed in Scilit:
- Localized Infant Neuroblastomas Often Show Spontaneous Regression: Results of the Prospective Trials NB95-S and NB97Journal of Clinical Oncology, 2008
- Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trialPediatric Blood & Cancer, 2007
- Significance of pleural effusion in neuroblastomaPediatric Blood & Cancer, 2007
- Surgical Risk Factors in Primary Surgery for Localized Neuroblastoma: The LNESG1 Study of the European International Society of Pediatric Oncology Neuroblastoma GroupJournal of Clinical Oncology, 2005
- Radically Different Treatment Recommendations for Newly Diagnosed Neuroblastoma: Pitfalls in Assessment of RiskJournal of Pediatric Hematology/Oncology, 2004
- Guidelines for radioiodinated MIBG scintigraphy in childrenEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Experience with International Neuroblastoma Staging System and Pathology ClassificationBritish Journal of Cancer, 2002
- Pulmonary Metastases at Diagnosis of Neuroblastoma in Pediatric PatientsAmerican Journal of Roentgenology, 2001
- Asymptotically Efficient Rank Invariant Test ProceduresJournal of the Royal Statistical Society. Series A (General), 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958